Istodax

DRUG2 trials

Sponsors

Weiyun Ai, Celgene

Conditions

Cutaneous LymphomaLymphomaLymphoma, T-Cell, PeripheralT-Cell Lymphoma

Phase 1

Phase I Dose-finding and Preliminary Efficacy Study of the Istodax® in Combination With Doxil® for the Treatment of Adults With Relapsed or Refractory Cutaneous T-cell Lymphoma

CompletedNCT01902225

Weiyun AiCutaneous Lymphoma, Lymphoma, T-Cell Lymphoma

Start: 2014-03-04End: 2020-04-11Updated: 2020-06-09

Unknown Phase

ISTODAX® for Intravenous Infusion Drug Use Results Survey- Relapsed or Refractory Peripheral T-Cell Lymphoma

CompletedNCT03742921

CelgeneLymphoma, T-Cell, Peripheral

Start: 2019-02-04End: 2023-10-31Updated: 2023-12-06